NNNicolas Novitzky

Nicolas Novitzky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas Novitzky has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Jacobs

    The University of Cape Town Leukaemia Centre and the Department of Haematology, Groote Schuur Hospital, Observatory, Cape, Cape Town

    2 shared publications
  • Regana Mohamed

    The University of Cape Town Leukaemia Centre and the Department of Haematology, Groote Schuur Hospital, Observatory, Cape, Cape Town, South Africa

    2 shared publications
  • Cecile E. du Toit

    University of Cape Town Leukaemia Centre and the Department of Haematology, Groote Schuur Hospital, Observatory 7925, Cape, South Africa

    1 shared publication
  • Cecile Toit

    The University of Cape Town Leukaemia Centre and the Department of Haematology, Groote Schuur Hospital, Observatory, Cape Town, South Africa

    1 shared publication
  • Cecile du Toit

    1 shared publication
  • For The European Society Of Paediatric Haematology And Immunology (Esphi) Myelodysplastic Syndromes (Mds) Working Party Gregor Prindull

    1 shared publication

Latest Publications

  • BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS FOLLOWED BY REPLETION WITH INCREMENTAL DOSES OF DONOR LYMPHOCYTES FOR RELAPSING PATIENTS WITH CHRONIC MYELOID LEUKEMIA

    by Nicolas Novitzky, Riva Rubinstein, Janet M. Hallett, Cecile E. du Toit, Valda L. Thomas

    Background. For patients with chronic myeloid leukemia (CML), long-term survival after stem cell transplantation requires adequate control of graft-versus-host disease (GVHD) and disease recurrence. Relapsing patients respond to donor lymphocyte infusion (DLI) but develop life-threatening complications. Methods. Patients with CML in first chronic phase received bone marrow (n=14) or peripheral blood progenitor cell transplants (n=4) from HLA-identical siblings. GVHD prophylaxis was by ex vivo T-cell depletion with CAMPATH 1G. If disease recurred, donors’ mononuclear cells were collected by apheresis, the CD3 samples commencing at 106/kg were aliquoted at half-log increment intervals, cryopreserved, and infused until disease clearance. Results. Eighteen patients (median age: 32.5 years) received transplants. All engrafted without procedure-related mortality. Fourteen patients relapsed, and 13 entered the DLI program. Two developed extensive GVHD after single schedule infusions ranging from 89×106 to 670×106 mononuclear cells/kg, and one survives in complete remission (CR). The rest, treated with incremental dose DLI, experienced no acute toxicities. One, who had developed grade III steroid-responsive GVHD, died in CR2 from opportunistic infections. Steroids reversed limited cutaneous GVHD and elevated liver enzymes in five patients. Three others developed pancytopenia, and two restored blood counts only after donor peripheral blood progenitor cell infusions. Molecular CR2 was established in 12/13 patients, occurring in 10/11 (91%) on the incremental program at a median accumulation of 67 (range: 5–166)×106 CD3 cells/kg. Sixteen of 18 (89%) survive at median of 854.5 days from bone marrow transplantation, 4 in CR1 and 10 in CR2 at a median disease-free survival (for remission 2) duration of 341 days. The median combined disease-free survival of the 14 patients in CR 1+2 is 660 days, with 99% average performance status. Conclusions. Escalating DLI leads to safe new molecular CR in most CML relapse patients. These results raise the possibility of using “safe” transplantation programs of T-cell depletion, that include graded DLI as prevention against disease recurrence.


  • Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management

    by Nicolas Novitzky, For The European Society Of Paediatric Haematology And Immunology (Esphi) Myelodysplastic Syndromes (Mds) Working Party Gregor Prindull

    The FAB group has defined myelodysplasia in adults but direct application of this categorization to children has been controversial. Consequently, to outline the natural history of the disease better we have retrospectively analysed case reports and series published in English between 1982 and 1996. This study also included children with juvenile chronic myelomonocytic leukaemia (JCML) and monosomy 7 (Mo7). 340 patients were described in 27 publications. The mean presentation age was 5.91 (SD 5.04) years, and 34.9% were female. Constitutional alterations were described in 68 (20%) where refractory anemia (RA) and RA with excess of blasts (RAEB) predominated and were associated with a significantly longer survival. Among all patients progression to higher forms of MDS was noted in 61 (18%). Cytogenetic anomalies were detected in 59% of 227 children, and in 67 it was to Mo7. Amid those with Mo7, the clinical and laboratory characteristics as well as survival, closely followed their FAB type. Of the treatment options described, survival was significantly higher in those who underwent bone marrow transplant (BMT) (46.9%; P = 0.00021). Among children with JMML (CMML/JCML) not receiving a BMT, time to death was shortest in those best described as JCML (absence of constitutional and karyotypic derangement, thrombocytopenia and elevated Hb F). We conclude that children with constitutional abnormalities survive longer, Mo7 disorders are clinically and morphologically heterogeneous and should not be grouped into a single entity and that CMML and JCML may have biological differences. Finally, BMT remains the treatment of choice for those with primary MDS, as intensive chemotherapy is no better than supportive measures. Am. J. Hematol. 63:212–222, 2000.


  • In aplastic anemia progenitor cells have a reduced sensitivity to the effects of growth factors

    by Nicolas Novitzky, Peter Jacobs

    Abstract:  We have recently shown that in patients with aplastic anemia (AA) recovering following immunosuppressive therapy, the persistent reduction in the bone marrow clonogenic potential is unrelated to suppressive effects of the myeloid stroma and intrinsic to the hematopoietic progenitors. We examined the mechanisms of this defect by determining the response of the aplastic CD34+ clonogenic precursors to proliferative signals induced by hematopoietic growth factors and comparing their results with those of a control population. Light density bone marrow mononuclear cells were lymphocyte and monocyte depleted and enhanced for the CD34+ progenitors by immunomagnetic selection. Selected progenitors were then cultured in the mixed colony assay with incremental concentrations of combinations containing erythropoietin (Epo), granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), interleukin‐3 (IL‐3) and c‐kit ligand. Bone marrow from aplastic patients had significantly fewer light density cells displaying the CD34 antigen (mean 0.65%, SD 0.35 vs. 1.62%, SD 1.4; p = 0.002). Dose response studies on aplastic CD34+ cells demonstrated that at low concentrations of Epo, IL‐3 and GM‐CSF, clonogenic growth was significantly impaired but achieved normal values at concentrations giving plateau growth in control cultures. However, for all colony types, responses to effective concentrations of c‐kit ligand corresponded with those of controls. These data suggest abnormalities at the receptor or signal transduction levels.


  • EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIA

    by Nicolas Novitzky, Valda Thomas, Geoffrey Hale, Herman Waldmann

    Background. Preventing graft-versus-host disease (GVHD) by depletion of T lymphocytes from the stem cell graft for transplantation remains controversial, mainly because of the perceived increase in disease recurrence. Methods. We retrospectively analyzed the outcome of 50 consecutive individuals in remission of acute lymphoblastic leukemia (n=13; 8 in complete remission [CR]1) or acute myeloblastic leukemia (n=37; 33 in CR1), who had received marrow grafts from HLA-identical siblings. The conditioning regimen included six 2-Gy fractions of total body irradiation, succeeded by cyclophosphamide at 120 mg/kg (with mesna) followed by four fractions of 1.5 Gy to lymphoid areas. Bone marrow (n=38) or peripheral blood mobilized donor mononuclear cells (n=12) were exposed ex vivo to CAMPATH-1 (IgM and complement, or IgG; anti-CD52) antibodies, without any further posttransplantation immunosuppression. Results. Median patient age was 31 (range 14-51) years; 12 patients were 40 or older. Thirty-two patients were male. One patient died of pulmonary hemorrhage on day 10; another died on day 29 of interstitial pneumonitis. Except for one early death, all patients engrafted. Ten (21%) of the remaining 48 who were at risk, developed GVHD. In none was it greater than grade II. Eight patients developed serious viral infections. Four died of cytomegalovirus pneumonia, adenovirus hepatitis, and human immunodeficiency. Overall, 11 patients (22%) relapsed (4 of 33 acute myeloblastic leukemia in CR1) at a median of 235 (range 46-528) days. Mean posttransplantation follow-up was 1062 (median 560; range 10-4177) days. Thirty-three patients (66%) remained disease free at a mean of 1,118 (median 1439; range 159-4,177) days. For all patients, the performance status was between 82% and 100% (median 100). Conclusion. T-cell depletion with CAMPATH-1 effectively prevents GVHD, particularly the severe acute forms, without leading to excessive risk of relapse in acute leukemia.


  • Acquired Aplasia of the Bone Marrow

    by Peter Jacobs, Nicolas Novitzky

    Supported by the University of Cape Town Leukaemia Centre and Staff Research (Foote, Becker and Cancer) Fund, the Gwendoline Moore Trust, the Cancer Association of South Africa, the Medical Research Council and the Michael Chanani, Kaliski and M A Richardson Bequests.